Faculty introduction, disclosures

Epidemiology and diagnosis of DLBCL ·       Statistics ·       Risk factors, pathophysiology ·       Clinical presentation and staging ·       Pathologic diagnosis and gene expression profiling ·       Double and triple expression, including prognostic implications

Management of DLBCL: Current guidelines, agents, and monitoring ·       Transplant-eligible vs. non-eligible ·       Goals of therapy and monitoring parameters ·       Initial therapy ·       CD-20 targeting ·       Therapy specific to molecular subtype ·       Subpopulations and clinical considerations: Germinal center vs. activated B cell types ·       Special populations: HIV/AIDS, CD20-negative, central nervous system lymphoma ·       Disease progression ·       Chimeric antigen receptor T cells ·       Chemo- and immunotherapy ·       Investigational and emerging therapies ·       Gaps in care ·       Patient cases

Summary, conclusions, and best practice recap

By the end of the session the participant will be able to:

• Recall goals of therapy and monitoring parameters in treating DLBCL
• Summarize present standards of care for the medical management of DLBCL
• Describe the mechanisms of action and places in therapy of present and investigational medications for DLBCL
• Formulate an individualized treatment regimen for a patient with DLBCL

ACCME Activity #201943115

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Faculty Disclosure:

Ranjit Nair, MD, Assistant Professor, The University of Texas MD Anderson Cancer Center, has no relevant financial disclosures.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty will discuss off-label uses.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Genmab and AbbVie.

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

*Required to view Printable PDF Version